Whoop Just Picked a Fight With the FDA. It Might Not Win.

Without premarket clearance (the FDA's formal stamp of approval), the agency declared Whoop's device "adulterated" and "misbranded" under federal law. The message was clear: get clearance or kill the feature.

Whoop did neither. BPI is still running in beta, and the company has publicly stated it "firmly disagrees" with the FDA's characterization.

A $10 Billion Gamble

This isn't some scrappy startup throwing rocks at a giant. Whoop raised $575 million in a Series G round in March 2026, valuing the company at $10.1 billion. Strategic backers include Abbott and the Mayo Clinic, which suggests Whoop has ambitions well beyond fitness tracking.

Founder and CEO Will Ahmed built Whoop from a project at the Harvard Innovation Lab in 2012 into one of the most valuable private wearable companies on the planet. The playbook has always been the same: win credibility with elite athletes, then go mainstream. The subscription model (roughly $30 a month; the device itself comes "free") has created a sticky, recurring revenue machine with millions of users worldwide.

But that growth strategy now collides with a fundamental tension. Whoop wants to offer increasingly sophisticated health insights to justify premium pricing. The FDA wants to make sure those insights don't mislead people about their health. Both sides have legitimate points, and the stakes keep climbing.

What Apple and Samsung Did Differently

Whoop isn't the only company putting blood pressure features on a wrist. But its competitors took very different regulatory paths.

Apple went the formal route. In September 2025, the FDA cleared its hypertension notification feature for Apple Watch. Crucially, Apple doesn't show you actual blood pressure numbers. It collects 30 days of optical sensor data, runs it through an algorithm, and simply alerts you if signs of high blood pressure appear. It's a nudge, not a diagnosis. Apple played by the FDA's rules and got its clearance.

Samsung took the other fork. When it brought blood pressure monitoring to Galaxy Watches in the U.S. in 2026, it leaned on the FDA's updated General Wellness Policy for Low-Risk Devices. That January 2026 update (partly shaped by the Whoop controversy itself) explicitly allows wearables to display blood pressure estimates as wellness data, provided they make zero diagnostic claims. Samsung stayed inside those lines.

Whoop, by contrast, launched BPI with marketing language that flirted with clinical utility, and when the FDA pushed back, it pushed back harder.

The Courtroom and the Classroom

The regulatory dispute isn't Whoop's only legal headache. The FDA's warning letter has already anchored a class-action lawsuit (Rowe v. Whoop), alleging the company marketed an unapproved medical device and misled consumers about the feature's accuracy and regulatory status.

Regulatory attorneys largely expect Whoop to lose if it presses a formal challenge. The FDA issued its warning letter just two months after first engaging with the company, which lawyers read as a signal of heightened enforcement urgency. Analysts at MedTech Dive have cited experts predicting the FDA is "not likely to concede."

The enforcement toolkit available to the FDA includes seizure, injunctions, and civil penalties. Several observers believe the agency may want to make an example of Whoop to send a message across the digital health landscape.

For Whoop users, the practical takeaway is simple: BPI is still available, but treat it as an experimental insight, not a substitute for a real blood pressure cuff or medical advice.

The Bigger Picture: Where Wellness Ends and Medicine Begins

This fight matters far beyond one company's beta feature. The core question is deceptively simple: if a wearable shows you numbers that look like a doctor's reading, is it practicing medicine?

The FDA's answer, increasingly, is yes. And that has massive implications for the roughly $90 billion wearables market. Expect higher compliance costs, longer development timelines, and a growing split between companies that embrace regulated device pathways and those that carefully restrict their claims to stay in the wellness lane.

Product designers now face a new reality: the user interface is a regulatory decision. Display exact blood pressure values with color-coded zones? That looks medical. Show a vague "cardiovascular load" score framed around recovery? That's wellness. The line between the two has never been thinner, or more consequential.

A Mayo Clinic cardiologist quoted in coverage of the dispute put the safety concern bluntly: false-low readings could delay care for someone heading toward a stroke, while false-high readings create unnecessary anxiety and doctor visits.

Whoop built its brand on the idea that more data makes you better. The FDA is asking a different question: does more data, without proper validation, make you safer? The answer to that question won't just decide Whoop's future. It'll shape what every wearable on your wrist is allowed to tell you.

Roche Just Crashed the Obesity Party With a Number Nobody Expected

Roche's obesity drug enicepatide posted 22.5% weight loss in 48 weeks, landing squarely in Zepbound territory and turning Roche from a latecomer into a legitimate contender. The real question: can it compete with what Lilly and Novo are cooking up next?